Turkey: Significant Reform For Turkish Patent Rights

Last Updated: 12 January 2017
Article by Işık Özdoğan, LL.M. and Merve Altınay

Turkey is on the verge of a new era for intellectual and industrial property rights, with enactment of the new Industrial Property Law ("IP Law"). As a result, the country's long discussed patent law practices are on the verge of substantial changes. The finalized IP Law was published in the Official Gazette on 10 January 2017, with the majority of provisions entering into effect on the same date.

The IP Law has been eagerly awaited in Turkey, since it unifies provisions for prosecution and enforcement of intellectual and industrial rights into a single Law (primary legislation). The move provides a solution to problems which have arisen in recent years due to intellectual and industrial rights finding their basis in Decree Laws (secondary legislation).

The Turkish Constitution states that (with limited exceptions) Decree Laws cannot regulate fundamental rights, nor may they regulate individual or political rights and duties, such as the right to property. Based on this restriction, the Constitutional Court has struck out certain articles of Decree Laws over recent years, which regulate trademarks, patents and industrial designs. Striking out such provisions caused a Turkey's overall legislative framework for intellectual and industrial property rights to be weakened.

Significant headline changes under the IP Law include with regards to patent rights include:

Post-Grant Opposition System:

The IP Law introduces a post-grant opposition system, whereby third parties can now oppose a patent within six months of publishing the decision stating that the patent is granted.

The grounds for such a patent opposition are:

  • The patent does not meet the patentability criteria.
  • The invention is not disclosed in a sufficient manner.
  • The patent exceeds the scope of the initial application.

Upon the Turkish Patent and Trademark Institute ("TPTI") notifying the patent owner about an opposition, the patent owner can file a response or amendments to the patent.

If the Re-examination and Evaluation Board ("Board") examines the opposition and finds that the patent conforms with the IP Law, it will refuse the opposition. If the Board concludes that the patent partially conforms to the law, it will confirm the partial validity. It will inform the patent owner accordingly, requesting the amendment of the patent in line with partial approval. If no amendments are filed (or the amendments are not approved), the patent will be invalidated.

Inventions By Scientific Staff In Higher Educational Institutions:

According to the IP Law, all inventions made by scientific staff (including regular students) while at work are deemed to be employee inventions, belonging to the university. The Decree Law previously stated that inventions by scientific staff in universities and other higher education institutions were free inventions. Therefore, the staff member would own the invention, rather than the university.

Under the change, the staff member must immediately notify the university of his/her invention. If the university does not claim the invention, it is deemed to be a free invention. If the university claims the invention, it must file a patent application. If the university does not duly file a patent application, the staff member receives the opportunity to file a patent application in his/her own name.

Compulsory License Criteria Expanded:

According to the prior Decree Law regime, a compulsory license will be granted in the event of:

  • Non-use of the patent.
  • Dependency of the patent's subject matter.
  • Matters of public interest.

The IP Law carries on these grounds for compulsory licenses, but also adds:

  • Export of pharmaceutical products in case of public health in other countries, in line with the TRIPS Agreement.
  • Plant breeder which cannot develop a new breed without infringing a patent.
  • Patent owner which behave in a manner to restrict, prevent or damage market competition.

The prior regime allowed the party requesting a compulsory license to apply to the TPTI, requesting its mediation, with a view to obtaining a contractual license for the patent. However, the IP Law directs disputes arising from compulsory licenses directly to first instance courts, without referring the matter to the TPTI as mediator.

Omission of Protection for Patents Granted Without Substantive Examination:

The IP Law makes it compulsory to request a substantive examination within three months of notification of the search report.

Previously, patent applicants could proceed with registration after the state-of-the-art search report, without being required to request a substantive examination. Such patents, granted without substantive examination, were simply granted a shorter protection term of seven years (compared to 20 years' protection, if the examination occurred).

Non-Patentable Biotechnological Inventions:

The IP Law expands the scope of non-patentable inventions. Accordingly, biological processes regarding plant or animal varieties or production thereof are considered non-patentable. An exception applies to microbiological process, or products obtained by means of such process.

Under the IP Law's reforms, the following are continue to be non-patentable inventions, but are added to the primary legislation, as opposed to the provisions' prior location in a Decree Law:

  • Processes for cloning human beings.
  • Processes for modifying the germ-line genetic identity of human beings.
  • Use of human embryos for industrial or commercial purposes.
  • Processes for modifying the genetic identity of animals which are likely to cause them suffering, without any substantial medical benefit to man or animal, as well as animals resulting from such processes.
  • Discovery of elements of the human body, at the various stages of formation and development, including the sequence or partial sequence of a gene.

However, the IP Law notably still lacks an explicit definition of "biotechnological inventions", as outlined by Article 52 of the EPC and Rules 27 and 29 of the Implementation Regulations.

Patentability of Second or Further Medical Use:

The IP Law's patentability criteria does not include provisions which correspond to Articles 5 and 54/4 of the European Patent Convention as revised in 2000. Therefore, Turkish legislation continues to not explicitly permit or prohibit second (or further) medical use.

Reviving Abandoned Patents Due To Non-Payment of Maintenance Fees:

The IP Law allows patent holders to revive a patent which has lapsed due to failure to pay the annual maintenance fee in time. To revive such a patent, the right holder must deposit penalty fee within two months of the TPTI notifying that the patent has lapsed. The patent will become valid again on for a further year, running from the fee payment date.

Lack Of Criminal Provisions for Patent Infringement:

When enacted, Decree Laws allowed patent owners to prosecute infringements criminally. However, the Constitutional Court subsequently cancelled such criminal provision and patent rights could no longer be enforced via criminal complaints.

Unfortunately, the IP Law has not changed this approach for patents. While it introduces criminal provisions for trademark infringements, the IP Law does not include criminal provisions for patents or industrial designs.

Pre-Emptive Declaratory Judgments:

Obtaining a declaratory judgment in which a court determines that infringement has not occurred ("non-infringement determination") is a key pre-emptive defensive measure for protecting intellectual property. Before initiating proceedings, the requesting party was previously required to send a notice to the Right Owner via a notary public. However, the wording in Decree Laws was unclear about whether this step was mandatory. The IP Law clarifies the notice step as not being compulsory for initiating such a non-infringement determination action.

* * *

The new IP law consolidates many articles of the Decree Law regime and accordingly many articles have been changed. Since the new legislation has now been enacted, it will soon be evident how the TPTI and first instance courts will apply the new provisions, as well as their approach to unregulated issues, such as second medical uses and biotechnological inventions.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

To print this article, all you need is to be registered on Mondaq.com.

Click to Login as an existing user or Register so you can print this article.

Işık Özdoğan, LL.M.
Merve Altınay
Similar Articles
Relevancy Powered by MondaqAI
Erdem & Erdem Law
Deris IP Attorneys
Some comments from our readers…
“The articles are extremely timely and highly applicable”
“I often find critical information not available elsewhere”
“As in-house counsel, Mondaq’s service is of great value”

Related Topics
Similar Articles
Relevancy Powered by MondaqAI
Erdem & Erdem Law
Deris IP Attorneys
Related Articles
Up-coming Events Search
Font Size:
Mondaq on Twitter
Register for Access and our Free Biweekly Alert for
This service is completely free. Access 250,000 archived articles from 100+ countries and get a personalised email twice a week covering developments (and yes, our lawyers like to think you’ve read our Disclaimer).
Email Address
Company Name
Confirm Password
Mondaq Topics -- Select your Interests
 Law Performance
 Law Practice
 Media & IT
 Real Estate
 Wealth Mgt
Asia Pacific
European Union
Latin America
Middle East
United States
Worldwide Updates
Registration (you must scroll down to set your data preferences)

Mondaq Ltd requires you to register and provide information that personally identifies you, including your content preferences, for three primary purposes (full details of Mondaq’s use of your personal data can be found in our Privacy and Cookies Notice):

  • To allow you to personalize the Mondaq websites you are visiting to show content ("Content") relevant to your interests.
  • To enable features such as password reminder, news alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our content providers ("Contributors") who contribute Content for free for your use.

Mondaq hopes that our registered users will support us in maintaining our free to view business model by consenting to our use of your personal data as described below.

Mondaq has a "free to view" business model. Our services are paid for by Contributors in exchange for Mondaq providing them with access to information about who accesses their content. Once personal data is transferred to our Contributors they become a data controller of this personal data. They use it to measure the response that their articles are receiving, as a form of market research. They may also use it to provide Mondaq users with information about their products and services.

Details of each Contributor to which your personal data will be transferred is clearly stated within the Content that you access. For full details of how this Contributor will use your personal data, you should review the Contributor’s own Privacy Notice.

Please indicate your preference below:

Yes, I am happy to support Mondaq in maintaining its free to view business model by agreeing to allow Mondaq to share my personal data with Contributors whose Content I access
No, I do not want Mondaq to share my personal data with Contributors

Also please let us know whether you are happy to receive communications promoting products and services offered by Mondaq:

Yes, I am happy to received promotional communications from Mondaq
No, please do not send me promotional communications from Mondaq
Terms & Conditions

Mondaq.com (the Website) is owned and managed by Mondaq Ltd (Mondaq). Mondaq grants you a non-exclusive, revocable licence to access the Website and associated services, such as the Mondaq News Alerts (Services), subject to and in consideration of your compliance with the following terms and conditions of use (Terms). Your use of the Website and/or Services constitutes your agreement to the Terms. Mondaq may terminate your use of the Website and Services if you are in breach of these Terms or if Mondaq decides to terminate the licence granted hereunder for any reason whatsoever.

Use of www.mondaq.com

To Use Mondaq.com you must be: eighteen (18) years old or over; legally capable of entering into binding contracts; and not in any way prohibited by the applicable law to enter into these Terms in the jurisdiction which you are currently located.

You may use the Website as an unregistered user, however, you are required to register as a user if you wish to read the full text of the Content or to receive the Services.

You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these Terms or with the prior written consent of Mondaq. You may not use electronic or other means to extract details or information from the Content. Nor shall you extract information about users or Contributors in order to offer them any services or products.

In your use of the Website and/or Services you shall: comply with all applicable laws, regulations, directives and legislations which apply to your Use of the Website and/or Services in whatever country you are physically located including without limitation any and all consumer law, export control laws and regulations; provide to us true, correct and accurate information and promptly inform us in the event that any information that you have provided to us changes or becomes inaccurate; notify Mondaq immediately of any circumstances where you have reason to believe that any Intellectual Property Rights or any other rights of any third party may have been infringed; co-operate with reasonable security or other checks or requests for information made by Mondaq from time to time; and at all times be fully liable for the breach of any of these Terms by a third party using your login details to access the Website and/or Services

however, you shall not: do anything likely to impair, interfere with or damage or cause harm or distress to any persons, or the network; do anything that will infringe any Intellectual Property Rights or other rights of Mondaq or any third party; or use the Website, Services and/or Content otherwise than in accordance with these Terms; use any trade marks or service marks of Mondaq or the Contributors, or do anything which may be seen to take unfair advantage of the reputation and goodwill of Mondaq or the Contributors, or the Website, Services and/or Content.

Mondaq reserves the right, in its sole discretion, to take any action that it deems necessary and appropriate in the event it considers that there is a breach or threatened breach of the Terms.

Mondaq’s Rights and Obligations

Unless otherwise expressly set out to the contrary, nothing in these Terms shall serve to transfer from Mondaq to you, any Intellectual Property Rights owned by and/or licensed to Mondaq and all rights, title and interest in and to such Intellectual Property Rights will remain exclusively with Mondaq and/or its licensors.

Mondaq shall use its reasonable endeavours to make the Website and Services available to you at all times, but we cannot guarantee an uninterrupted and fault free service.

Mondaq reserves the right to make changes to the services and/or the Website or part thereof, from time to time, and we may add, remove, modify and/or vary any elements of features and functionalities of the Website or the services.

Mondaq also reserves the right from time to time to monitor your Use of the Website and/or services.


The Content is general information only. It is not intended to constitute legal advice or seek to be the complete and comprehensive statement of the law, nor is it intended to address your specific requirements or provide advice on which reliance should be placed. Mondaq and/or its Contributors and other suppliers make no representations about the suitability of the information contained in the Content for any purpose. All Content provided "as is" without warranty of any kind. Mondaq and/or its Contributors and other suppliers hereby exclude and disclaim all representations, warranties or guarantees with regard to the Content, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. To the maximum extent permitted by law, Mondaq expressly excludes all representations, warranties, obligations, and liabilities arising out of or in connection with all Content. In no event shall Mondaq and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use of the Content or performance of Mondaq’s Services.


Mondaq may alter or amend these Terms by amending them on the Website. By continuing to Use the Services and/or the Website after such amendment, you will be deemed to have accepted any amendment to these Terms.

These Terms shall be governed by and construed in accordance with the laws of England and Wales and you irrevocably submit to the exclusive jurisdiction of the courts of England and Wales to settle any dispute which may arise out of or in connection with these Terms. If you live outside the United Kingdom, English law shall apply only to the extent that English law shall not deprive you of any legal protection accorded in accordance with the law of the place where you are habitually resident ("Local Law"). In the event English law deprives you of any legal protection which is accorded to you under Local Law, then these terms shall be governed by Local Law and any dispute or claim arising out of or in connection with these Terms shall be subject to the non-exclusive jurisdiction of the courts where you are habitually resident.

You may print and keep a copy of these Terms, which form the entire agreement between you and Mondaq and supersede any other communications or advertising in respect of the Service and/or the Website.

No delay in exercising or non-exercise by you and/or Mondaq of any of its rights under or in connection with these Terms shall operate as a waiver or release of each of your or Mondaq’s right. Rather, any such waiver or release must be specifically granted in writing signed by the party granting it.

If any part of these Terms is held unenforceable, that part shall be enforced to the maximum extent permissible so as to give effect to the intent of the parties, and the Terms shall continue in full force and effect.

Mondaq shall not incur any liability to you on account of any loss or damage resulting from any delay or failure to perform all or any part of these Terms if such delay or failure is caused, in whole or in part, by events, occurrences, or causes beyond the control of Mondaq. Such events, occurrences or causes will include, without limitation, acts of God, strikes, lockouts, server and network failure, riots, acts of war, earthquakes, fire and explosions.

By clicking Register you state you have read and agree to our Terms and Conditions